CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock, Par Value	Additional Paid in Capital	Deficit Accumulated during the Development Stage	Non-Controlling interest
Balance at Nov. 15, 2005
Increase (Decrease) in Stockholders' Equity
Sale of unregistered common stock to founder	$ 2	$ 7	$ (5)
Sale of unregistered common stock to founder (in shares)		75,690,608
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	18	1	17
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		6,850,000
Balance at Dec. 31, 2005	20	8	12
Balance (in shares) at Dec. 31, 2005		82,540,608
Increase (Decrease) in Stockholders' Equity
Net loss for the period	(20)			(20)
Balance at Dec. 31, 2006		8	12	(20)
Balance (in shares) at Dec. 31, 2006		82,540,608
Increase (Decrease) in Stockholders' Equity
Capital contribution by shareholders	9		9
Net loss for the period	(20)			(20)
Balance at Dec. 31, 2007	(11)	8	21	(40)
Balance (in shares) at Dec. 31, 2007		82,540,608
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	3,025		3,025
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		2,520,833
Fees and expenses related to financing transactions, including controlled equity sales	(73)		(73)
Stock based compensation expense	380		380
Cancellation of unregistered shares		(7)	7
Cancellation of unregistered shares (in shares)		(74,990,604)
Common stock issued via exchange transactions to former Callisto Shareholders and other	27,280	3	27,277
Common stock issued via exchange transactions to former Callisto Shareholders and other (in shares)		22,732,380
Net loss for the period	(31,757)			(31,757)
Balance at Dec. 31, 2008	(1,156)	4	30,637	(31,797)
Balance (in shares) at Dec. 31, 2008		32,803,217
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	15,970	1	15,969
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		11,407,213
Fees and expenses related to financing transactions, including controlled equity sales	(260)		(260)
Stock based compensation expense	1,052		1,052
Common stock issued for services rendered	2		2
Common stock issued for services rendered (in shares)		1,250
Net loss for the period	(8,124)			(8,124)
Balance at Dec. 31, 2009	7,484	5	47,400	(39,921)
Balance (in shares) at Dec. 31, 2009		44,211,680
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	7,179		7,179
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		1,209,000
Fees and expenses related to financing transactions, including controlled equity sales	(468)		(468)
Stock based compensation expense	694		694
Warrants classified to derivative liability	(3,785)		(3,785)
Common stock issued to extend lock-up agreements related to unregistered shares (in shares)		670,933
Common stock issued for services rendered	18		18
Common stock issued for services rendered (in shares)		2,469
Net loss for the period	(15,221)			(15,221)
Balance at Dec. 31, 2010	(4,099)	5	51,038	(55,142)
Balance (in shares) at Dec. 31, 2010		46,094,082
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	34,369	1	34,368
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		7,733,093
Fees and expenses related to financing transactions, including controlled equity sales	(2,148)		(2,148)
Stock based compensation expense	481		481
Fees and expenses related to financing transactions - paid in units of common stock and warrants (in shares)		77,750
Warrants classified to derivative liability	(5,094)		(5,094)
Common stock issued to make whole certain unregistered shares (in shares)		215,981
Exercise of warrant	415		415
Exercise of warrant (in shares)		80,000
Common stock issued for services rendered	341		341
Common stock issued for services rendered (in shares)		79,000
Net loss for the period	(14,467)			(14,467)
Balance at Dec. 31, 2011	9,798	6	79,401	(69,609)
Balance (in shares) at Dec. 31, 2011		54,279,906
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	55,862	1	55,861
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		12,315,654
Fees and expenses related to financing transactions, including controlled equity sales	(3,774)		(3,774)
Stock based compensation expense	2,297		2,297
Common stock issued for services rendered	93		93
Common stock issued for services rendered (in shares)		26,272
Net loss for the period	(39,444)			(39,444)
Balance at Dec. 31, 2012	24,832	7	133,878	(109,053)
Balance (in shares) at Dec. 31, 2012		66,621,832
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	94,734	2	94,732
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		17,133,093
Fees and expenses related to financing transactions, including controlled equity sales	(5,623)		(5,623)
Stock based compensation expense	4,489		4,489
Exercise of stock options	119		119
Exercise of stock options (in shares)		61,787
Cancellation of unregistered shares		(2)	2
Cancellation of unregistered shares (in shares)		(22,294,976)
Common stock issued via exchange transactions to former Callisto Shareholders and other		3	(3)
Common stock issued via exchange transactions to former Callisto Shareholders and other (in shares)		28,605,379
Fair value of warrants reclassified to additional paid in capital	3,575		3,575
Recapitalization of Synergy	(4,904)		(4,904)
Common stock issued for services rendered	250		250
Common stock issued for services rendered (in shares)		55,000
Net loss for the period	(62,124)			(62,124)
Balance at Dec. 31, 2013	55,348	10	226,515	(171,177)
Balance (in shares) at Dec. 31, 2013	90,182,115	90,182,115
Increase (Decrease) in Stockholders' Equity
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements	22,606		22,606
Common stock issued pursuant to a controlled equity "at-the-market" sales agreement, via registered direct offerings, and via private placements (in shares)		3,872,392
Fees and expenses related to financing transactions, including controlled equity sales	(624)		(624)
Stock based compensation expense	1,264		1,264
Exercise of stock options	36		36
Exercise of stock options (in shares)		9,999
Private placement of ContraVir common stock	3,224		3,224
Fees and expenses associated with ContraVir Private Placement	(15)		(15)
Fair value of warrants issued in connection with ContraVir private placement	(880)		(880)
Noncontrolling interest of ContraVir	(1,622)				(1,622)
Distribution of ContraVir common stock to Synergy shareholders	(1,740)		(1,740)
Elimination of noncontrolling interest of ContraVir upon distribution	1,622				1,622
Net loss for the period	(16,225)			(16,225)
Balance at Mar. 31, 2014	$ 62,994	$ 10	$ 250,386	$ (187,402)
Balance (in shares) at Mar. 31, 2014	94,064,506	94,064,506